Recently, the National Health Commission (NHC) officially announced that the 3'-Sialyllactose sodium salt (3'-SL) independently developed by Synaura Biotechnology has passed the safety evaluation as a "New Food Raw Material, New Food Additive, or New Food-Related Product" and has been successfully approved as a novel nutritional fortifier. This marks the first official approval of 3'-SL in China, signaling a new phase in both regulatory oversight and industrial development for Human Milk Oligosaccharides (HMOs) in this country. With this achievement, Synaura Biotechnology has become China's first and only company to have secured NHC approvals for 2'-Fucosyllactose (2'-FL), Lacto-N-neotetraose (LNnT), and now 3'-Sialyllactose sodium salt (3'-SL).

As a naturally occurring functional trisaccharide in human milk, 3'-SL is a significant acidic member of the HMO family and has garnered substantial industry attention due to its diverse physiological benefits. Clinical research and authoritative data indicate that 3'-SL not only provides critical support for infant brain development but also possesses excellent prebiotic properties, effectively regulating gut microbiota balance. Furthermore, its positive roles in enhancing immune function and improving inflammatory responses have been widely validated, offering new directions for nutritional interventions in specific populations.

The successful NHC approval of 3'-SL not only represents high recognition of Hongmo's R&D system, safety assessment capabilities, and engineering proficiency but also signifies continuous breakthroughs in China's biosynthetic and industrial pathways for HMOs. As a domestic frontrunner in HMOs, Synaura Biotechnology will continue to deepen its product portfolio, accelerate the large-scale production of high-standard ingredients, and promote the high-quality application of local HMOs in infant nutrition and life health sectors.

About Synaura Biotechnology

Synaura Biotechnology is a joint venture established by China's leading dairy enterprise, Mengniu Group (Stock Code: 2319.HK), and Abiochem, a representative enterprise in China's synthetic biology sector. It stands as a pioneer in the independent R&D and industrialization of Human Milk Oligosaccharides (HMOs) in China, as well as an innovator in synthetic biology, mastering advanced synthetic biology technologies. Currently, Synaura Biotechnology has successfully developed over ten product lines, spanning biopharmaceuticals, green agriculture, and health foods, among other fields. Extensive application validation has shown that Synaura's HMO products are of superior quality, renowned for their high purity, uniform particle size, absence of acetic acid odor residues, and compatibility with both dry and wet processing methods, ensuring ease of application. Synaura Biotechnology remains committed to independent innovation and industrial practice, dedicated to providing hundreds of millions of Chinese families with high-quality HMO ingredients, delivering more health and care.